Who should have pelvic vessel imaging prior to renal transplantation?

Clinical Transplantation

Volumn 25, Issue 1, 2011, Pages 97-103

  Subesinghe, Manil ^a   Cherukuri, Aravind ^b   Ecuyer, Clare ^c   Baker, Richard James ^c  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b Renal Medicine   (United Kingdom)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Angiography; End stage renal disease; Kidney transplantation; Magnetic resonance angiography; Peripheral arterial disease

Indexed keywords

ADULT; ARTICLE; CLINICAL DECISION MAKING; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HIGH RISK POPULATION; HUMAN; KIDNEY BLOOD VESSEL; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MAGNETIC RESONANCE ANGIOGRAPHY; MAJOR CLINICAL STUDY; MALE; PELVIS ANGIOGRAPHY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRACTICE GUIDELINE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK FACTOR;

AGE FACTORS; CONTRAST MEDIA; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY TRANSPLANTATION; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; PELVIS; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RENAL INSUFFICIENCY; RESEARCH DESIGN; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 79551709932     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2010.01218.x     Document Type: Article

References (39)

1. Ansell D, Feehally J, Fogarty D, Tomson C, Williams AJ, Warwick G. UK Renal Registry. Bristol, UK: UK Renal Registry Report 2008.
2. Wolfe RA, Ashby VB, Milford EL et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation and recipients of a first cadaveric transplant. N Eng J Med 1999: 341: 1725.
3. Alfrey EJ, Smythe R, Friedman A et al. Two masqueraders of transplant renal artery stenosis (TRAS). Clin Transplant 1993: 7: 183.
4. Brekke IB, Lien B, Sødal G et al. Aortoiliac reconstruction in preparation for renal transplantation. Transpl Int 1993: 6: 161.
5. Sung RS, Althoen M, Howell TA, Merion RM. Peripheral vascular occlusive disease in renal transplant recipients: risk factors and impact on kidney allograft survival. Transplantation 2000: 70: 1049.
6. Webb AT, Franks PJ, Reaveley DA, Greenhalgh RM, Brown EA. Prevalence of intermittent claudication and risk factors for its development in patients on renal replacement therapy. Eur J Vasc Endovasc Surg 1993: 7: 523.
7. Leskinen Y, Salenius JP, Lehtimäki T, Huhtala H, Saha H. Prevalence of peripheral arterial disease and medial arterial calcification in patients with chronic renal failure: requirements for diagnostics. Am J Kidney Dis 2002: 40: 472.
8. Kasiske BL, Guijarro C, Massy ZA, Wiederkehr MR, Ma JZ. Cardiovascular disease after renal transplantation. J Am Soc Nephrol 1996: 7: 158.
9. Aakhus S, Dahl K, Widerøe TE. Cardiovascular morbidity and risk factors in renal transplant patients. Nephrol Dial Transplant 1999: 14: 648.
10. Snyder JJ, Kasiske BL, Maclean R. Peripheral arterial disease and renal transplantation. J Am Soc Nephrol 2006: 17: 56.
11. Eggers PW, Gohdes D, Pugh J. Nontraumatic lower extremity amputations in the Medicare end-stage renal disease population. Kidney Int 1999: 56: 1524.
12. Jaar BG, Astor BC, Berns JS, Powe NR. Predictors of amputation and survival following lower extremity revascularisation in haemodialysis patients. Kidney Int 2004: 65: 613.
13. Phillips GWL. Review of arterial vascular ultrasound. World J Surg 2000: 24: 232.
14. Collins R, Burch J, Cranny G et al. Duplex ultrasonography, magnetic resonance angiography and computed tomography angiography for diagnosis and assessment of symptomatic, lower limb peripheral arterial disease: systematic review. BMJ 2007: 334: 1257.
15. Josephs SC, Rowley HA, Rubin GD. Atherosclerotic peripheral vascular disease symposium II: vascular magnetic resonance and computed tomographic imaging. Circulation 2008: 118: 2837.
16. Met R, Bipat S, Legemate DA, Reekers JA, Koelemay MJW. Diagnostic performance of computed tomography angiography in peripheral arterial disease. JAMA 2009: 301: 415.
17. Cowie A. Renal Imaging in patients requiring renal replacement therapy. Semin Dial 2002: 15: 237.
18. Moranne O, Willoteaux S, Pagniez D, Dequiedt P, Boulanger E. Effect of iodinated contrast agents on residual renal function in PD patients. Nephrol Dial Transplant 2006: 21: 1040.
19. Venkataraman V, Nolph KD. Preservation of residual renal function - an important goal. Perit Dial Int 2000: 20: 392.
20. Chandna SM, Farrington K. Residual renal function: considerations on its importance and preservation in dialysis patients. Semin Dial 2004: 17: 196.
21. Singhal MK, Bhaskaran S, Vidgen E, Bargman JM, Vas SI, Oreopoulos DG. Rate of decline of residual renal function in patients on continuous peritoneal dialysis and factors affecting it. Perit Dial Int 2000: 20: 429.
22. Visser K, Hunink MG. Peripheral arterial disease: gadolinium-enhanced MR angiography versus colour-guided duplex US - a meta-analysis. Radiology 2000: 216: 67.
23. Cowper SE, Su LD, Bhawan J, Robin HS, Leboit PE. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 2001: 23: 383.
24. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006: 21: 1104.
25. Marckmann P, Skov L, Rossen K et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006: 17: 2359.
26. Martin DR. Nephrogenic systemic fibrosis: a radiologist's perspective. Eur J Radiol 2008: 66: 220.
27. Saab G, Abu-Alfa A. Nephrogenic systemic fibrosis: implications for nephrologists. Eur J Radiol 2008: 66: 208.
28. Thomson HS, Morcos SK, Dawson P. Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)? Clin Radiol 2006: 61: 905.
29. U.S Food and Drug Administration. Public Health Advisory: Gadolinium-Containing Contrast Agents for Magnetic Resonance Imaging (MRI). Available at: Accessed 8th June 2009.
30. Okada S, Katagiri K, Kumazaki T, Yokoyama H. Safety of gadolinium contrast agents in haemodialysis patients. Acta Radiol 2001: 42: 339.
31. Medicines and Healthcare Products Regulatory Agency. Nephrogenic Systemic Fibrosis (NSF) and gadolinium-containing MRI contrast agents. Available at Accessed 10th October 2009.
32. Kasiske BL, Cangro CB, Hariharan S et al. The evaluation of renal transplant candidates: clinical practice guidelines. Am J Transplant 2001: 2(Suppl. 1): S5.
33. EBPG (European Expert Group on Renal Transplantation); European Renal Association (ERA-EDTA); European Society for Organ Transplantation (ESOT). European Best Practice Guidelines for Renal Transplantation (part 1). Evaluation, selection and preparation of the potential transplant recipient. Nephrol Dial Transplant 2000: 15(Suppl 7): 3.
34. Knoll G, Cockfield S, Blydt-Hansen T et al. Canadian society of transplantation: consensus guidelines on eligibility for kidney transplantation. CMAJ 2005: 173: S1.
35. Burgos FJ, Pascual J, Marcen R, García-Navas R, Gómez V, Ortuño J. The role of imaging techniques in renal transplantation. World J Urol 2004: 22: 399.
36. Becker BN, Odorico JS, Becker YT et al. Peripheral vascular disease and renal transplant artery stenosis: a reappraisal of transplant renovascular disease. Clin Transplant 1999: 13: 349.
37. Scandling JD. Kidney transplant candidate evaluation. Semin Dial 2005: 18: 487.
38. Centers for Disease Control Prevention (CDC). Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents, St. Louis, Missouri, 2002-2006. MMWR Morb Mortal Wkly Rep 2007: 56: 137.
39. Finn WF. The clinical and renal consequences of contrast-induced nephropathy. Nephrol Dial Transplant 2006: 21: 2.